SCHEMBL8736734

SCHEMBL8736734

Cc1ccc(Oc2ccc(Cl)c(Cl)c2)nc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.57
POLB P06746 1/20 0.57
HAO1 Q9UJM8 2/20 0.51
HRH3 Q9Y5N1 3/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HTR2A P28223 3/20 0.47
SLC6A4 P31645 3/20 0.47
KCNH2 Q12809 3/20 0.47
KMO O15229 1/20 0.46
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GAA P10253 1/20 0.42
HSP90AA1 P07900 1/20 0.42
S1PR2 O95136 1/20 0.39
S1PR4 O95977 1/20 0.39
S1PR3 Q99500 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4598208 0.81 KDM4E (0.54) KDM4EPOLBHAO1HRH3MEN1
SCHEMBL6506841 0.80 KDM4E (0.75) KDM4EPOLBHAO1HRH3MEN1
SCHEMBL2974010 0.80 HAO1 (0.51) KDM4EPOLBHAO1HRH3MEN1
SCHEMBL8737052 0.80 KDM4E (0.66) KDM4EPOLBMEN1KMT2ANPC1
SCHEMBL10921859 0.80 KDM4E (0.50) KDM4EPOLBHAO1HRH3MEN1
SCHEMBL20718225 0.78 KDM4E (0.47) KDM4EPOLBMEN1KMT2ANPC1
SCHEMBL10834026 0.77 KDM4E (0.48) KDM4EPOLBHAO1HRH3MEN1
SCHEMBL10923178 0.77 KDM4E (0.48) KDM4EPOLBHAO1HRH3MEN1
SCHEMBL8736869 0.77 HAO1 (0.51) KDM4EPOLBHAO1MEN1KMT2A
SCHEMBL328392 0.77 RAB9A (0.47) KDM4EPOLBMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas DUMAS JACQUES (US) 2012-05-24 US disclosed
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas DUMAS JACQUES (US) 2012-05-24 US disclosed
US-20080269265-A1 Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas MILLER SCOTT 2008-10-30 US disclosed
US-20080269265-A1 Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas MILLER SCOTT 2008-10-30 US disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BRAF, RAF1, ARAF KDM4E 1353/4885POLB 2254/4885HAO1 3065/4885
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas BRAF, RAF1, ARAF KDM4E 1353/4885POLB 2254/4885HAO1 3065/4885
US-20080269265-A1 Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas BRAF, RAF1, MAP2K2 KDM4E 1268/4885POLB 2606/4885HAO1 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.